JPMorgan Chase & Co. Purchases 16,274 Shares of Anika Therapeutics Inc. (ANIK)

JPMorgan Chase & Co. raised its position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 2,781.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,859 shares of the biotechnology company’s stock after purchasing an additional 16,274 shares during the period. JPMorgan Chase & Co.’s holdings in Anika Therapeutics were worth $982,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in shares of Anika Therapeutics during the 3rd quarter worth about $118,000. Stevens Capital Management LP purchased a new stake in shares of Anika Therapeutics during the 3rd quarter worth about $222,000. Victory Capital Management Inc. raised its stake in shares of Anika Therapeutics by 17.6% during the 2nd quarter. Victory Capital Management Inc. now owns 4,060 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 608 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Anika Therapeutics by 3.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,315 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 126 shares in the last quarter. Finally, Miles Capital Inc. purchased a new stake in shares of Anika Therapeutics during the 2nd quarter worth about $232,000. 84.91% of the stock is owned by institutional investors.

Anika Therapeutics Inc. (NASDAQ:ANIK) opened at $56.64 on Friday. Anika Therapeutics Inc. has a one year low of $41.64 and a one year high of $60.29. The firm has a market capitalization of $823.70, a P/E ratio of 26.38, a P/E/G ratio of 3.40 and a beta of 1.44.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.05. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The business had revenue of $27.18 million for the quarter, compared to the consensus estimate of $27.44 million. During the same period last year, the business earned $0.59 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. equities analysts anticipate that Anika Therapeutics Inc. will post 1.9 EPS for the current year.

In related news, CEO Charles H. Sherwood sold 5,991 shares of the firm’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $60.04, for a total value of $359,699.64. Following the transaction, the chief executive officer now directly owns 158,297 shares of the company’s stock, valued at approximately $9,504,151.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Charles H. Sherwood sold 22,228 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $60.06, for a total value of $1,335,013.68. Following the completion of the transaction, the chief executive officer now directly owns 158,297 shares in the company, valued at $9,507,317.82. The disclosure for this sale can be found here. Insiders sold a total of 36,762 shares of company stock worth $2,178,445 over the last three months. 6.57% of the stock is owned by company insiders.

A number of equities research analysts have recently weighed in on the company. Barrington Research reaffirmed a “buy” rating and set a $57.00 price target on shares of Anika Therapeutics in a research note on Thursday, December 28th. BidaskClub raised Anika Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th.

COPYRIGHT VIOLATION NOTICE: “JPMorgan Chase & Co. Purchases 16,274 Shares of Anika Therapeutics Inc. (ANIK)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/01/13/jpmorgan-chase-co-purchases-16274-shares-of-anika-therapeutics-inc-anik.html.

About Anika Therapeutics

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit